WideMed Ltd. (TASE:WDMD) has received three orders for its Morpheus Hx sleep disorder diagnostic device from GE Healthcare. GE Healthcare will integrate the devices with its Mars VLS devices at US hospitals. The company did not disclose the value of the order
WideMed president CEO Anya Eldan said, "We are pleased by this follow-on order from GE Healthcare for US hospitals. The product has won a vote of confidence from GE, which is expanding its marketing efforts to customers interested in the unique technology."
Widemed has developed computerized diagnostic devices that monitor, analyze, and save biometric signals related to sleep apnea. The company has three products certified for marketing in Europe, two products certified for marketing in the US, and another product undergoing regulatory procedures with the US Food and Drug Administration (FDA).
WideMed's share price rose 3% by midday to NIS 0.54, giving a market cap of NIS 8.8 million.
Published by Globes [online], Israel business news - www.globes-online.com - on August 10, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011